# Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma

> **NCT01976208** · PHASE2,PHASE3 · COMPLETED · sponsor: **Shanghai Zhangjiang Biotechnology Limited Company** · enrollment: 630 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01976208
- **Lead sponsor:** Shanghai Zhangjiang Biotechnology Limited Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 630 (ACTUAL)
- **Last updated:** 2015-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01976208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01976208, "Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01976208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*